Navigation Links
Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination
Date:5/20/2008

Endoscopic ablative therapy with HALO device leads to 100% patient response

rate

SUNNYVALE, Calif., May 20 /PRNewswire/ -- BARRX Medical, Inc., a global technology leader in treating Barrett's esophagus, today announced the publication of two related European trials which report a 100% eradication rate for early esophageal cancer and pre-cancerous dysplasia using endoscopic resection followed by ablation therapy with the HALO ablation system. Barrett's esophagus is a complication of gastroesophageal reflux disease (GERD) and is a known risk factor for esophageal cancer, the fastest growing cancer in the Western world.

Results of the two studies were published in the May issue of Endoscopy, a medical journal for gastroenterologists performing advanced endoscopic procedures. They were titled "Effective treatment of early Barrett's neoplasia with stepwise circumferential and focal ablation using the HALO system," and "Stepwise circumferential and focal ablation of Barrett's esophagus with high- grade dysplasia: results of the first prospective series of 11 patients." The investigators enrolled patients with Barrett's esophagus having early cancer and/or advanced dysplasia, used endoscopic resection to remove focal abnormal areas, then used endoscopic ablative therapy with the HALO system to eradicate all remaining diseased tissue. At one and two year follow-up, respectively, in each trial, all patients were cured of their esophageal disease.

"This data confirms that early cancer and advanced dysplasia can be safely and effectively treated with this non-surgical approach using endoscopic resection and ablation," said Amsterdam Medical Centre (AMC) gastroenterologist and Professor of Medicine Jacques Bergman, M.D., who led the study in Amsterdam, the Netherlands. "We're confident this treatment can reduce the need for high risk surgical procedures and become the preferred strategy for treating patients with Ba
'/>"/>

SOURCE BARRX Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Saving Lives of California Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment
3. Saving Lives of Florida Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment
4. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
5. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
6. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
7. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
8. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
9. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
10. Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies
11. Potential Early Warning System for Lung Cancer Identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)...., Oct. 7 /- A study published in the...m cell self-renewal,reported that InVitria,s ( ht...an serum albumin) was an effective replacement to ...icle entitled, "The ground state of embryonic stem...ed Cellastim as a recombinant,albumin in place of ...
(Date:10/7/2008)...Oct. 7 /- Aerovance Inc. today report...se I trial of its Aerovant,inhalation powder that ...local irritancy following asthma patients, inhalat... be the highest of three doses investigated in,Aer...heduled to begin early,next year. Evidence gathere...
(Date:10/7/2008).../- Ardea Biosciences, Inc.,...itled "RDEA119, a Potent,and Highly Selective MEK1...um (DSS) -- induced Chronic Colitis in Mice," was ...ogy (ACG) 2008 Annual Meeting in Orlando,Florida....l study of,RDEA119, the Company,s lead mitogen-act...
(Date:10/7/2008)...k, October 7 /-, - 125 Pat...ase II Study,Shows Statistically Significant Impro...luated the mature phase II data from the,therapeut...that had been,obtained as part of the recently ent...e (NCI) in the US., The results from the Phase II...
Breaking Medicine Technology:Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 5Lack of Time on Tummy Shown to Hinder Achievement of Developmental Milestones Say Physical Therapists 25084 1Lack of Time on Tummy Shown to Hinder Achievement of Developmental Milestones Say Physical Therapists 25084 2Lack of Time on Tummy Shown to Hinder Achievement of Developmental Milestones Say Physical Therapists 25084 3Lack of Time on Tummy Shown to Hinder Achievement of Developmental Milestones Say Physical Therapists 25084 4Brain Slow to Judge Fast Moving Objects Head On 25082 1Brain Slow to Judge Fast Moving Objects Head On 25082 2Autistic Children Make Limited Eye Contact 25080 1Autistic Children Make Limited Eye Contact 25080 2Autistic Children Make Limited Eye Contact 25080 3AUDIO from Medialink and BP 3A Younger for Longer 25078 1
...007 - CeNeS Pharmaceuticals (AIM:CEN),("CeNeS" or ...al,company today announced that a paper published ...othesis that a,catechol-O-methyltransferase (COMT)...l agent to address profound cognitive,deficits in ...ngoing discovery programme to develop novel COMT i...
...at Eight Weeks Sustained up to 12 Weeks,and Drug R... Calif., July 02, 2007,/PRNewswire-FirstCall/ -- A...rm, follow-up results from a Phase 2 study showing...5) in patients with,moderate-to-severe osteoarthri... pain that persisted for up to 12 weeks. , "The po...
Other Medicine Technology:Major New Review Supports the Broader Potential of CeNeS COMT,Inhibitor Discovery Programme 2Major New Review Supports the Broader Potential of CeNeS COMT,Inhibitor Discovery Programme 3Major New Review Supports the Broader Potential of CeNeS COMT,Inhibitor Discovery Programme 4Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain,Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the,Knee 2Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain,Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the,Knee 3Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain,Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the,Knee 4Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain,Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the,Knee 5
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...Infirmary in Scotland will be the first in United ...eration in recipient. The Health Minister Andy Ker...ld be done followed by ten the next year//. In li...f liver is transplanted and regenerated following ...
Canadians flocking to India for quick and efficient medical treatment
...ab) drug is found to be useful in treating patient...by the European Medicines Agency (EMEA) for use in...rent drugs//. Xolair can be used in the treatment ...ffects of the new drug on long time usage has to b...
...suggests that the melanocortin system is an import...l neuronal plasticity observed after chronic morph...is accompanied by the development of morphine tole...s associated with opiate treatment. Possible modul...
Other Medicine News:Health News:Inhibition of morphine tolerance by spinal melanocortin receptor blockade 2
Cholesterol/HDL Standard 50 mg/dl.
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol
Ready to use liquid single reagent for automated chemistry analyzers. Linearity to 1000 mmol/L
Ammonia reagent is used for the quantitative and enzymatic determination of ammonia in human plasma.
Medicine Products: